HYPE3 after 2Q26: Sell-out beats the market as gross margin rises — but marketing spend compresses EBITDA while cash pays down debt

On 6 August 2026, Hypera Pharma (B3: HYPE3; NYSE: HYP) released 2Q26 results for the period ended 30 June 2026. Net revenue reached R$ 2.34 billion (+8.5% year on year). Gross margin expanded 1.7 percentage points to 61.8%, yet EBITDA from continuing operations grew only 4.1% to R$ 754.9 million, with margin slipping to 32.3% from 33.7% in 2Q25. Net income from continuing operations rose 15.0% to R$ 490.0 million — faster than EBITDA — helped by a smaller negative financial result. Operating cash flow hit R$ 819.2 million (108.5% of continuing EBITDA), free cash flow reached R$ 637.8 million, and net debt (post hedge) fell R$ 397.6 million quarter on quarter to R$ 5.90 billion (2.1× annualized continuing EBITDA).

The educational frame is margin layering in branded pharma. Hypera sells through pharmacy retail sell-out (consumer purchases), not shelf invoices alone. When volume and price/mix lift gross profit but marketing, sales, and G&A scale faster than revenue, EBITDA margin can fall even in a good demand quarter. Readers who followed RADL3's digital-led pharmacy growth see the other side of the counter: a retailer gaining share with a thin EBITDA margin and deleveraging. Hypera is the supplier with high gross and EBITDA margins — and a balance sheet still carrying ~R$ 5.9 billion of net debt that management is explicitly paying down with cash.

Consolidated snapshot

Management highlighted retail sell-out growth of 7.6% in the quarter — about 1.4 percentage points above its reference market — with contributions from gastroenterology, cardiology, and dermatology, and roughly 2.2 percentage points of sell-out growth from launches in the last twelve months. Those are company narratives to cross-check in the ITR annexes, not independent market data in this article.

Demand versus P&L: why revenue grew faster than EBITDA

Hypera's top line and gross profit tell a constructive demand story:

Below gross profit, operating expenses grew faster than revenue in the period (figures from public earnings coverage aligned with the release):

That pattern explains the EBITDA margin compression: gross margin expansion was not enough to offset commercial and overhead deleverage. For pharma investors, this is the recurring trade-off between brand investment (launches, categories, share of voice) and short-term EBITDA. Hypera's 32.3% margin is still structurally high versus pharmacy retail peers, but the −1.4 pp year-on-year move matters when debt sits at 2.1× EBITDA.

Net income: financial lines, not operating acceleration

Net income grew 15% while EBITDA grew 4%. Public coverage of the release attributed part of the beat to a lower negative net financial result — about R$ 176.7 million in the quarter, an improvement of roughly 17% versus the prior-year quarter. That does not reduce the importance of operating cash generation, but it does mean headline EPS is not a clean proxy for operating momentum this quarter.

When reconciling filings, separate:

1. Continuing operations (core pharma) — the metrics above.
2. Financial expense and hedge accounting — can move net income independently of sell-out.
3. First-half 2026 year-on-year percentages — the company's 1H26 tables show very large gains versus 1H25 on some lines; use 2Q26 for like-for-like quarter analysis unless you explicitly adjust the base.

Cash flow and working capital: the deleveraging engine

The quarter's balance-sheet story is cash conversion funding debt reduction:

Management framed lower working-capital intensity as a driver of cash — consistent with net debt falling R$ 397.6 million from 1Q26 to R$ 5.90 billion at 30 June 2026. Leverage at 2.1× (net debt over annualized continuing EBITDA) is moderate for Brazilian corporates but still material; the direction (down in the quarter) matters as much as the level.

Capital return appeared via interest on equity (JCP) of R$ 185.2 million (R$ 0.26 per share), declared with the results — a Brazil-specific payout form to verify against the dividend/JCP note in the CVM filing.

How to read the next filing

1. Track sell-out vs revenue — invoicing timing can diverge from pharmacy scanner data.
2. Bridge gross margin to EBITDA margin through marketing and sales lines; a launch year often shows gross up, EBITDA flat.
3. Reconcile EBITDA to net income through financial expense — do not annualize one quarter's derivative or FX noise without reading the footnotes.
4. Pair FCF with working-capital ratios; improving cash conversion can coexist with EBITDA margin pressure.
5. For retail channel context, compare with RADL3 (share, CMED, digital) and NATU3 (Brazil consumption headwinds).

Where to see this on the explorer

• HYPE3 company page
• Blog index

Sources

• Hypera Pharma S.A. — 2Q26 earnings / performance commentary for the period ended 30 June 2026, disclosed 6 August 2026 (CVM)
• Valor Econômico — Hypera 2Q26 earnings coverage (6 August 2026)
• UOL Economia / Estadão e-investidor — 2Q26 results summaries (August 2026)
• HYPE3 on the explorer

Disclaimer

This article is for informational and educational purposes only. It is not investment advice. Continuing versus consolidated figures, hedge-adjusted debt, and EBITDA definitions follow Hypera's earnings materials and may differ from statutory IFRS lines in CVM filings. Sell-out statistics, launch contributions, and leverage ratios can move quarter to quarter. Refer to official documents and, if needed, a licensed professional.